1. Home
  2. NCNA

NCNA

NuCana plc

Logo NuCana plc

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-19-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.

Founded: N/A Country:
United Kingdom
United Kingdom
Employees: N/A City: N/A
Market Cap: 13.7M IPO Year: 2017
Target Price: $5.00 AVG Volume (30 days): 71.9K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -16.39 EPS Growth: N/A
52 Week Low/High: $0.21 - $0.96 Next Earning Date: 05-15-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: